Literature DB >> 35169959

Role of Surfactants on Release Performance of Amorphous Solid Dispersions of Ritonavir and Copovidone.

Anura S Indulkar1,2, Xiaochun Lou1, Geoff G Z Zhang3, Lynne S Taylor4.   

Abstract

PURPOSE: To understand the role of different surfactants, incorporated into amorphous solid dispersions (ASDs) of ritonavir and copovidone, in terms of their impact on release, phase behavior and stabilization of amorphous precipitates formed following drug release.
METHODS: Ternary ASDs with ritonavir, copovidone and surfactants (30:70:5 w/w/w) were prepared by rotary evaporation. ASD release performance was tested using Wood's intrinsic dissolution rate apparatus and compared to the binary drug-polymer ASD with 30% drug loading. Size measurement of amorphous droplets was performed using dynamic light scattering. Solid state characterization was performed using attenuated total reflectance-infrared spectroscopy, differential scanning calorimetry and scanning electron microscopy.
RESULTS: All surfactant-containing ASDs showed improvement over the binary ASD. Span 85 and D-α-tocopheryl polyethylene glycol succinate (TPGS) showed complete release with no evidence of AAPS or crystallization whereas Span 20 and Tween 80 showed < 50% release with amorphous amorphous phase separation (AAPS). Span 20 also induced solution crystallization. Sodium dodecyl sulfate (SDS) showed very rapid, albeit incomplete (~ 80%) release. AAPS was not observed with SDS. However, crystallization on the dissolving solid surface was noted. Span 20 and TPGS formed the smallest and most size-stable droplets with ~ 1 µm size whereas coalescence was noted with other surfactants.
CONCLUSIONS: Surfactants improved the release performance relative to the binary ASD. Different surfactant types impacted overall performance to varying extents and affected different attributes. Overall, Span 85 showed best performance (complete release, no crystallization/AAPS and small droplet size). Correlation between physicochemical properties and surfactant performance was not observed.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  amorphous solid dispersion; droplets; release; surfactant

Mesh:

Substances:

Year:  2022        PMID: 35169959     DOI: 10.1007/s11095-022-03183-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  43 in total

1.  What is the true solubility advantage for amorphous pharmaceuticals?

Authors:  B C Hancock; M Parks
Journal:  Pharm Res       Date:  2000-04       Impact factor: 4.200

Review 2.  Amorphous solid dispersions: a robust platform to address bioavailability challenges.

Authors:  Ann Newman; Karthik Nagapudi; Robert Wenslow
Journal:  Ther Deliv       Date:  2015-02

3.  Insight into Amorphous Solid Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer Measurements.

Authors:  Siddhi S Hate; Susan M Reutzel-Edens; Lynne S Taylor
Journal:  Mol Pharm       Date:  2018-12-18       Impact factor: 4.939

Review 4.  Strategies to address low drug solubility in discovery and development.

Authors:  Hywel D Williams; Natalie L Trevaskis; Susan A Charman; Ravi M Shanker; William N Charman; Colin W Pouton; Christopher J H Porter
Journal:  Pharmacol Rev       Date:  2013-01       Impact factor: 25.468

Review 5.  Assessing the performance of amorphous solid dispersions.

Authors:  Ann Newman; Gregory Knipp; George Zografi
Journal:  J Pharm Sci       Date:  2011-12-27       Impact factor: 3.534

6.  Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach.

Authors:  Satomi Onoue; Hideyuki Sato; Kumiko Ogawa; Yohei Kawabata; Takahiro Mizumoto; Kayo Yuminoki; Naofumi Hashimoto; Shizuo Yamada
Journal:  Int J Pharm       Date:  2010-08-10       Impact factor: 5.875

7.  Manufacturing strategies to develop amorphous solid dispersions: An overview.

Authors:  Nicole Mendonsa; Bjad Almutairy; Venkata Raman Kallakunta; Sandeep Sarabu; Priyanka Thipsay; Suresh Bandari; Michael A Repka
Journal:  J Drug Deliv Sci Technol       Date:  2019-12-11       Impact factor: 3.981

8.  The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane.

Authors:  Arik Dahan; Avital Beig; Viktoriya Ioffe-Dahan; Riad Agbaria; Jonathan M Miller
Journal:  AAPS J       Date:  2012-12-15       Impact factor: 4.009

9.  Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process.

Authors:  Navnit Shah; Raman M Iyer; Hans-Juergen Mair; Duk Soon Choi; Hung Tian; Ralph Diodone; Karsten Fähnrich; Anni Pabst-Ravot; Kin Tang; Emmanuel Scheubel; Joseph F Grippo; Sebastian A Moreira; Zenaida Go; James Mouskountakis; Theresa Louie; Prabha N Ibrahim; Harpreet Sandhu; Linda Rubia; Hitesh Chokshi; Dharmendra Singhal; Waseem Malick
Journal:  J Pharm Sci       Date:  2012-12-29       Impact factor: 3.534

10.  Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study.

Authors:  Michael Kennedy; Jack Hu; Ping Gao; Lan Li; Alana Ali-Reynolds; Ben Chal; Vicki Gupta; Chandra Ma; Nidhi Mahajan; Anna Akrami; Sekhar Surapaneni
Journal:  Mol Pharm       Date:  2008 Nov-Dec       Impact factor: 4.939

View more
  1 in total

Review 1.  Continuous Manufacturing and Molecular Modeling of Pharmaceutical Amorphous Solid Dispersions.

Authors:  Amritha G Nambiar; Maan Singh; Abhishek R Mali; Dolores R Serrano; Rajnish Kumar; Anne Marie Healy; Ashish Kumar Agrawal; Dinesh Kumar
Journal:  AAPS PharmSciTech       Date:  2022-09-02       Impact factor: 4.026

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.